WallStreetZenWallStreetZen

NASDAQ: SMMT
Summit Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SMMT

Based on 5 analysts offering 12 month price targets for Summit Therapeutics Inc

Min Forecast
$18.00+13.92%
Avg Forecast
$33.60+112.66%
Max Forecast
$40.00+153.16%

Should I buy or sell SMMT stock?

Based on 5 analysts offering ratings for Summit Therapeutics Inc.

Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SMMT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SMMT as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their SMMT stock forecasts and price targets.

SMMT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-24
lockedlocked$00.00+00.00%2026-01-30
lockedlocked$00.00+00.00%2025-12-17
lockedlocked$00.00+00.00%2025-10-22
lockedlocked$00.00+00.00%2025-10-20

1 of 1

Forecast return on equity

Is SMMT forecast to generate an efficient return?

Company
178.46%
Industry
215.41%
Market
239.49%
SMMT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SMMT forecast to generate an efficient return on assets?

Company
156.52%
Industry
99.34%
SMMT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SMMT earnings per share forecast

What is SMMT's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
-$0.95
Avg 2 year Forecast
-$0.87
Avg 3 year Forecast
$0.18

SMMT revenue forecast

What is SMMT's revenue in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
$17.8M
Avg 2 year Forecast
$126.8M
Avg 3 year Forecast
$912.2M

SMMT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SMMT$15.80$33.60+112.66%Buy
BMRN$61.11$85.46+39.85%Strong Buy
JAZZ$188.97$219.18+15.99%Strong Buy
EXEL$44.28$44.36+0.19%Buy
IONS$80.60$90.16+11.86%Strong Buy
View Top Biotech Stocks

Summit Therapeutics Stock Forecast FAQ

Is Summit Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: SMMT) stock is to Buy SMMT stock.

Out of 5 analysts, 2 (40%) are recommending SMMT as a Strong Buy, 2 (40%) are recommending SMMT as a Buy, 1 (20%) are recommending SMMT as a Hold, 0 (0%) are recommending SMMT as a Sell, and 0 (0%) are recommending SMMT as a Strong Sell.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.

What is SMMT's earnings growth forecast for 2026-2028?

(NASDAQ: SMMT) Summit Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 38.53%.

Summit Therapeutics's earnings in 2026 is -$1,079,586,000.On average, 18 Wall Street analysts forecast SMMT's earnings for 2026 to be -$733,114,888, with the lowest SMMT earnings forecast at -$1,205,937,160, and the highest SMMT earnings forecast at -$455,919,148. On average, 15 Wall Street analysts forecast SMMT's earnings for 2027 to be -$678,296,038, with the lowest SMMT earnings forecast at -$1,299,369,571, and the highest SMMT earnings forecast at -$447,777,734.

In 2028, SMMT is forecast to generate $136,155,446 in earnings, with the lowest earnings forecast at -$522,368,588 and the highest earnings forecast at $1,681,008,014.

What is SMMT's revenue growth forecast for 2026-2028?

(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.49%.

Summit Therapeutics's revenue in 2026 is $0.On average, 16 Wall Street analysts forecast SMMT's revenue for 2026 to be $13,826,445,986, with the lowest SMMT revenue forecast at $0, and the highest SMMT revenue forecast at $66,759,589,470. On average, 15 Wall Street analysts forecast SMMT's revenue for 2027 to be $98,278,489,725, with the lowest SMMT revenue forecast at $0, and the highest SMMT revenue forecast at $332,658,149,481.

In 2028, SMMT is forecast to generate $707,287,223,213 in revenue, with the lowest revenue forecast at $59,159,386,265 and the highest revenue forecast at $2,385,046,425,200.

What is SMMT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SMMT) forecast ROA is 156.52%, which is higher than the forecast US Biotechnology industry average of 99.34%.

What is SMMT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year SMMT price target, the average SMMT price target is $33.60, with the highest SMMT stock price forecast at $40.00 and the lowest SMMT stock price forecast at $18.00.

On average, Wall Street analysts predict that Summit Therapeutics's share price could reach $33.60 by Feb 24, 2027. The average Summit Therapeutics stock price prediction forecasts a potential upside of 112.66% from the current SMMT share price of $15.80.

What is SMMT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SMMT) Summit Therapeutics's current Earnings Per Share (EPS) is -$0.01. On average, analysts forecast that SMMT's EPS will be -$0.95 for 2026, with the lowest EPS forecast at -$1.56, and the highest EPS forecast at -$0.59. On average, analysts forecast that SMMT's EPS will be -$0.87 for 2027, with the lowest EPS forecast at -$1.68, and the highest EPS forecast at -$0.58. In 2028, SMMT's EPS is forecast to hit $0.18 (min: -$0.67, max: $2.17).

What is SMMT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SMMT) forecast ROE is 178.46%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.